NEW YORK (GenomeWeb) – Lucigen has signed a licensing agreement to take over the manufacture and sale of a portfolio of transposomics, microarray analysis, and transcriptomics products from Illumina subsidiary Epicentre, GenomeWeb has learned.
The exclusive agreement covers a variety of research products including ones from Epicentre's AmpliScribe, CopyControl, MaxPlax, and TransforMax lines. According to Lucigen, the products complement its suite of synthetic biology, next-generation sequencing, genetic amplification, and protein expression tools.
Lucigen said that it will begin offering the products directly to its customers and through its worldwide distribution network beginning on Jan. 1, 2017.
Additional terms of the deal were not disclosed.
"We are excited to expand and enrich our product offering to serve scientists worldwide with unique tools that will deliver innovative and meaningful breakthroughs in life sciences," Lucigen CEO Ralph Kauten said in a statement.